Compare American Superconductor Corporation (AMSC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Zoetis Inc — how do they compare? American Superconductor Corporation trades at $32.48 (market cap $1.56B), while Zoetis Inc trades at $73.83 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 20× American Superconductor Corporation's market cap, and Zoetis Inc pays a 2.81% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | ZTS | |
|---|---|---|
Market Cap | $1.56B | $31.14B |
Sector | Technology | Health |
52-Week High | $66.68 | $156.76 |
52-Week Low | $25.95 | $71.91 |
Enterprise Value | $1.42B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.
The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
